View Financial HealthBarito Pacific 配当と自社株買い配当金 基準チェック /06Barito Pacific配当を支払う会社であり、現在の利回りは0.057%です。主要情報0.06%配当利回り0.06%バイバック利回り総株主利回り0.1%将来の配当利回り0.3%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新お知らせ • Feb 04PT Barito Pacific Tbk (IDX:BRPT) announces an Equity Buyback for IDR 1,000,000 million worth of its shares.PT Barito Pacific Tbk (IDX:BRPT) announces a share repurchase program. Under the plan, the company will repurchase up to IDR 1,000,000 million worth of its shares. The program will be fully funded by internal cash balance. The purpose of the program is to provide flexibility to achieve an efficient capital structure and reflect the Company's performance through the company's share price. Repurchased shares will be held as treasury shares and transferred within 3 years of completion. The program will expire on May 3, 2026.すべての更新を表示Recent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 4 highly experienced directors. No independent directors (4 non-independent directors). Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • May 20PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026.お知らせ • Feb 04PT Barito Pacific Tbk (IDX:BRPT) announces an Equity Buyback for IDR 1,000,000 million worth of its shares.PT Barito Pacific Tbk (IDX:BRPT) announces a share repurchase program. Under the plan, the company will repurchase up to IDR 1,000,000 million worth of its shares. The program will be fully funded by internal cash balance. The purpose of the program is to provide flexibility to achieve an efficient capital structure and reflect the Company's performance through the company's share price. Repurchased shares will be held as treasury shares and transferred within 3 years of completion. The program will expire on May 3, 2026.Board Change • Dec 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. No independent directors (4 non-independent directors). Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • May 14PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025. Location: jakarta Indonesiaお知らせ • Apr 25PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion.PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion on April 21, 2025. A cash consideration of IDR 90 billion will be paid by PT Buana Primatama Niaga and PT Chandra Daya Investasi for 20,390 shares. The composition of BIP's share ownership after the share acquisition has changed. CDI is now the majority shareholder in BIP, namely 20,399 shares worth IDR 20.39 billion (99.99%). The remaining 1 share (1%) or worth IDR 1 million is owned by BPN. In order to support this transformation, BRPT and GI intend to transfer all share ownership in BIP to the CAP Group and its affiliates, namely BIP and BPN, so that the logistics business line can be more focused on being developed by the CAP Group. The object of this affiliate transaction is all shares owned by BRPT and all shares owned by GI in BIP with a total of 20,400 shares or representing 100% of all shares issued in BIP. The value of this transaction is recorded at IDR 90 billion. Kantor Jasa Penilai Publik Syarif, Endang & Partners acted as fairness opinion provider for PT Barito Pacific Tbk.Reported Earnings • Nov 01Third quarter 2024 earnings released: EPS: US$0 (vs US$0 in 3Q 2023)Third quarter 2024 results: EPS: US$0 (in line with 3Q 2023). Revenue: US$517.9m (down 30% from 3Q 2023). Net loss: US$7.69m (down 240% from profit in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change).Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: US$0 (vs US$0 in 2Q 2023)Second quarter 2024 results: EPS: US$0 (in line with 2Q 2023). Revenue: US$540.6m (down 25% from 2Q 2023). Net income: US$25.6m (up 262% from 2Q 2023). Profit margin: 4.7% (up from 1.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.お知らせ • May 12PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024.Buy Or Sell Opportunity • May 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.3% to €0.049. The fair value is estimated to be €0.04, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 78%. Revenue is forecast to grow by 13% in a year. Earnings are forecast to grow by 1,155% in the next year.Reported Earnings • May 03First quarter 2024 earnings released: EPS: US$0 (vs US$0 in 1Q 2023)First quarter 2024 results: EPS: US$0 (in line with 1Q 2023). Revenue: US$618.6m (down 4.9% from 1Q 2023). Net income: US$8.86m (down 62% from 1Q 2023). Profit margin: 1.4% (down from 3.6% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.Buy Or Sell Opportunity • Apr 02Now 21% overvaluedOver the last 90 days, the stock has fallen 28% to €0.048. The fair value is estimated to be €0.039, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 61%. Revenue is forecast to grow by 4.5% in 2 years. Earnings are forecast to grow by 349% in the next 2 years.Reported Earnings • Mar 30Full year 2023 earnings released: EPS: US$0 (vs US$0 in FY 2022)Full year 2023 results: EPS: US$0 (in line with FY 2022). Revenue: US$2.76b (down 6.8% from FY 2022). Net income: US$26.1m (up US$24.4m from FY 2022). Profit margin: 0.9% (up from 0.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Buy Or Sell Opportunity • Mar 08Now 24% overvaluedOver the last 90 days, the stock has fallen 46% to €0.051. The fair value is estimated to be €0.041, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.Buy Or Sell Opportunity • Feb 22Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 5.3% to €0.05. The fair value is estimated to be €0.041, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.Buy Or Sell Opportunity • Feb 07Now 34% overvalued after recent price riseOver the last 90 days, the stock has risen 34% to €0.067. The fair value is estimated to be €0.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$0 (vs US$0 in 3Q 2022)Third quarter 2023 results: EPS: US$0 (in line with 3Q 2022). Revenue: US$738.1m (down 2.8% from 3Q 2022). Net income: US$5.48m (up 123% from 3Q 2022). Profit margin: 0.7% (up from 0.3% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$0 (vs US$0 in 2Q 2022)Second quarter 2023 results: EPS: US$0 (in line with 2Q 2022). Revenue: US$723.5m (down 10.0% from 2Q 2022). Net income: US$7.08m (up US$7.59m from 2Q 2022). Profit margin: 1.0% (up from net loss in 2Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Reported Earnings • Jun 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: US$650.7m (down 20% from 1Q 2022). Net income: US$23.3m (up 149% from 1Q 2022). Profit margin: 3.6% (up from 1.1% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 02Second quarter 2022 earnings released: EPS: US$0 (vs US$0.001 in 2Q 2021)Second quarter 2022 results: EPS: US$0 (down from US$0.001 in 2Q 2021). Revenue: US$804.3m (down 3.0% from 2Q 2021). Net loss: US$509.0k (down 101% from profit in 2Q 2021). Revenue is forecast to decline by 3.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (3 non-independent directors). President Commissioner Prajogo Pangestu is the most experienced director on the board, commencing their role in 1993. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Reported Earnings • Apr 06Full year 2021 earnings released: EPS: US$0.001 (vs US$0 in FY 2020)Full year 2021 results: EPS: US$0.001 (up from US$0 in FY 2020). Revenue: US$3.16b (up 35% from FY 2020). Net income: US$109.1m (up 201% from FY 2020). Profit margin: 3.5% (up from 1.6% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.1%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Jul 01PT Barito Pacific to Be Deleted from Other OTCPT Barito Pacific TBK Ordinary Shares will be deleted from Other OTC effective July 01, 2021. The deletion is due to Inactive Security.Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: US$2.33b (down 2.8% from FY 2019). Net income: US$36.3m (down 18% from FY 2019). Profit margin: 1.6% (down from 1.8% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.決済の安定と成長配当データの取得安定した配当: OB8はGerman市場で注目すべき配当金を支払っていないため、支払いが安定しているかどうかを確認する必要はありません。増加する配当: OB8はGerman市場で注目すべき配当金を支払っていないため、支払額が増加しているかどうかを確認する必要はありません。配当利回り対市場Barito Pacific 配当利回り対市場OB8 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (OB8)0.06%市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Chemicals)3.7%アナリスト予想 (OB8) (最長3年)0.3%注目すべき配当: OB8の配当金 ( 0.057% ) はGerman市場の配当金支払者の下位 25% ( 1.54% ) と比べると目立ったものではありません。高配当: OB8の配当金 ( 0.057% ) はGerman市場の配当金支払者の上位 25% ( 4.55% ) と比較すると低いです。株主への利益配当収益カバレッジ: OB8の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: OB8は配当金を支払っていますが、同社にはフリーキャッシュフローがありません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 10:42終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PT Barito Pacific Tbk 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Justian Rama LiusudarsoCitigroup IncArnanto JanuriJ.P. MorganRichardo WalujoMacquarie Research5 その他のアナリストを表示
お知らせ • Feb 04PT Barito Pacific Tbk (IDX:BRPT) announces an Equity Buyback for IDR 1,000,000 million worth of its shares.PT Barito Pacific Tbk (IDX:BRPT) announces a share repurchase program. Under the plan, the company will repurchase up to IDR 1,000,000 million worth of its shares. The program will be fully funded by internal cash balance. The purpose of the program is to provide flexibility to achieve an efficient capital structure and reflect the Company's performance through the company's share price. Repurchased shares will be held as treasury shares and transferred within 3 years of completion. The program will expire on May 3, 2026.
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 4 highly experienced directors. No independent directors (4 non-independent directors). Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • May 20PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026.
お知らせ • Feb 04PT Barito Pacific Tbk (IDX:BRPT) announces an Equity Buyback for IDR 1,000,000 million worth of its shares.PT Barito Pacific Tbk (IDX:BRPT) announces a share repurchase program. Under the plan, the company will repurchase up to IDR 1,000,000 million worth of its shares. The program will be fully funded by internal cash balance. The purpose of the program is to provide flexibility to achieve an efficient capital structure and reflect the Company's performance through the company's share price. Repurchased shares will be held as treasury shares and transferred within 3 years of completion. The program will expire on May 3, 2026.
Board Change • Dec 30No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. No independent directors (4 non-independent directors). Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • May 14PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025. Location: jakarta Indonesia
お知らせ • Apr 25PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion.PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion on April 21, 2025. A cash consideration of IDR 90 billion will be paid by PT Buana Primatama Niaga and PT Chandra Daya Investasi for 20,390 shares. The composition of BIP's share ownership after the share acquisition has changed. CDI is now the majority shareholder in BIP, namely 20,399 shares worth IDR 20.39 billion (99.99%). The remaining 1 share (1%) or worth IDR 1 million is owned by BPN. In order to support this transformation, BRPT and GI intend to transfer all share ownership in BIP to the CAP Group and its affiliates, namely BIP and BPN, so that the logistics business line can be more focused on being developed by the CAP Group. The object of this affiliate transaction is all shares owned by BRPT and all shares owned by GI in BIP with a total of 20,400 shares or representing 100% of all shares issued in BIP. The value of this transaction is recorded at IDR 90 billion. Kantor Jasa Penilai Publik Syarif, Endang & Partners acted as fairness opinion provider for PT Barito Pacific Tbk.
Reported Earnings • Nov 01Third quarter 2024 earnings released: EPS: US$0 (vs US$0 in 3Q 2023)Third quarter 2024 results: EPS: US$0 (in line with 3Q 2023). Revenue: US$517.9m (down 30% from 3Q 2023). Net loss: US$7.69m (down 240% from profit in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change).
Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: US$0 (vs US$0 in 2Q 2023)Second quarter 2024 results: EPS: US$0 (in line with 2Q 2023). Revenue: US$540.6m (down 25% from 2Q 2023). Net income: US$25.6m (up 262% from 2Q 2023). Profit margin: 4.7% (up from 1.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 4.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
お知らせ • May 12PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024.
Buy Or Sell Opportunity • May 07Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 4.3% to €0.049. The fair value is estimated to be €0.04, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 78%. Revenue is forecast to grow by 13% in a year. Earnings are forecast to grow by 1,155% in the next year.
Reported Earnings • May 03First quarter 2024 earnings released: EPS: US$0 (vs US$0 in 1Q 2023)First quarter 2024 results: EPS: US$0 (in line with 1Q 2023). Revenue: US$618.6m (down 4.9% from 1Q 2023). Net income: US$8.86m (down 62% from 1Q 2023). Profit margin: 1.4% (down from 3.6% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.
Buy Or Sell Opportunity • Apr 02Now 21% overvaluedOver the last 90 days, the stock has fallen 28% to €0.048. The fair value is estimated to be €0.039, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 61%. Revenue is forecast to grow by 4.5% in 2 years. Earnings are forecast to grow by 349% in the next 2 years.
Reported Earnings • Mar 30Full year 2023 earnings released: EPS: US$0 (vs US$0 in FY 2022)Full year 2023 results: EPS: US$0 (in line with FY 2022). Revenue: US$2.76b (down 6.8% from FY 2022). Net income: US$26.1m (up US$24.4m from FY 2022). Profit margin: 0.9% (up from 0.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Buy Or Sell Opportunity • Mar 08Now 24% overvaluedOver the last 90 days, the stock has fallen 46% to €0.051. The fair value is estimated to be €0.041, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.
Buy Or Sell Opportunity • Feb 22Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 5.3% to €0.05. The fair value is estimated to be €0.041, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.
Buy Or Sell Opportunity • Feb 07Now 34% overvalued after recent price riseOver the last 90 days, the stock has risen 34% to €0.067. The fair value is estimated to be €0.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 50%. Revenue is forecast to grow by 7.6% in 2 years. Earnings are forecast to grow by 333% in the next 2 years.
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$0 (vs US$0 in 3Q 2022)Third quarter 2023 results: EPS: US$0 (in line with 3Q 2022). Revenue: US$738.1m (down 2.8% from 3Q 2022). Net income: US$5.48m (up 123% from 3Q 2022). Profit margin: 0.7% (up from 0.3% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$0 (vs US$0 in 2Q 2022)Second quarter 2023 results: EPS: US$0 (in line with 2Q 2022). Revenue: US$723.5m (down 10.0% from 2Q 2022). Net income: US$7.08m (up US$7.59m from 2Q 2022). Profit margin: 1.0% (up from net loss in 2Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Reported Earnings • Jun 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: US$650.7m (down 20% from 1Q 2022). Net income: US$23.3m (up 149% from 1Q 2022). Profit margin: 3.6% (up from 1.1% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 02Second quarter 2022 earnings released: EPS: US$0 (vs US$0.001 in 2Q 2021)Second quarter 2022 results: EPS: US$0 (down from US$0.001 in 2Q 2021). Revenue: US$804.3m (down 3.0% from 2Q 2021). Net loss: US$509.0k (down 101% from profit in 2Q 2021). Revenue is forecast to decline by 3.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (3 non-independent directors). President Commissioner Prajogo Pangestu is the most experienced director on the board, commencing their role in 1993. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Reported Earnings • Apr 06Full year 2021 earnings released: EPS: US$0.001 (vs US$0 in FY 2020)Full year 2021 results: EPS: US$0.001 (up from US$0 in FY 2020). Revenue: US$3.16b (up 35% from FY 2020). Net income: US$109.1m (up 201% from FY 2020). Profit margin: 3.5% (up from 1.6% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.1%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Jul 01PT Barito Pacific to Be Deleted from Other OTCPT Barito Pacific TBK Ordinary Shares will be deleted from Other OTC effective July 01, 2021. The deletion is due to Inactive Security.
Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: US$2.33b (down 2.8% from FY 2019). Net income: US$36.3m (down 18% from FY 2019). Profit margin: 1.6% (down from 1.8% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.